Bone Biologics (NASDAQ:BBLG – Get Free Report) and TransMedics Group (NASDAQ:TMDX – Get Free Report) are both healthcare companies, but which is the better business? Analyst RatingsThis is a summary of current ratings for Bone Biologics and TransMedics Group, as reported by MarketBeat. Given TransMedics Group’s stronger consensus rating and higher probable upside, analysts plainly believe TransMedics Group is more favorable than Bone Biologics. ProfitabilityNet Margins Return on Equity Return on Assets Bone Biologics N/A -50.47% -47.40% TransMedics Group 22.69% 15.88% 5.95%Volatility and RiskThis table compares Bone Biologics and TransMedics Group’s net margins, return on equity and return on assets. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bone Biologics N/A N/A -$3.11 million ($2.27) -0.41 TransMedics Group $605.49 million 4.79 $190.29 million $3.89 21.57TransMedics Group has higher revenue and earnings than Bone Biologics.